ACCC COVID-19 Resource Center & Discussion Group
for Insights on Providing Optimal Patient Care During the Pandemic.
providing a voice for Hawaii's MULTIDISCIPLINARY CANCER CARE TEAMS and the PATIENTS THEY SERVE since 1996
Meetings & Education
Medical Aid in Dying
HSCO Patient Education Videos
State & Federal Resources
Off-Label Use Literature
Patient Advocacy Organizations
National Professional Organizations
HSCO Corporate Members
Become a Corporate Member
Industry News Archive
COVID-19 Featured Resources
FDA Approves Erdafitinib for Metastatic Urothelial Carcinoma
On April 12, the Food and Drug Administration granted accelerated approval to erdafitinib (Balversa, Janssen Pharmaceutical Companies) for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations, that has progressed during or following platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
The FDA also approved the
FGFR RGQ RT-PCR Kit developed by Qiagen for use as a companion diagnostic for this therapeutic indication.
Read the full FDA press release here.